Prospective studies with largercohorts, including baseline measurements of copeptin and selectin, and assessment ofclinical outcomes such as the development of diabetes mellitus, gestational diabetesmellitus, or cardiovascular events, are necessary to clarify the potential role ofthese biomarkers in these phenotypes. This evidence concerns the gene AVP and diabetes mellitus.